Unique ID issued by UMIN | UMIN000022731 |
---|---|
Receipt number | R000025839 |
Scientific Title | A phase II clinical trial of carbon-ion radiotherapy for pelvic recurrent rectal cancer in patients with prior pelvic carbon-ion irradiation |
Date of disclosure of the study information | 2016/06/14 |
Last modified on | 2023/06/21 13:45:00 |
A phase II clinical trial of carbon-ion radiotherapy for pelvic recurrent rectal cancer in patients with prior pelvic carbon-ion irradiation
Carbon-ion re-irradiation for pelvic recurrent rectal cancer
A phase II clinical trial of carbon-ion radiotherapy for pelvic recurrent rectal cancer in patients with prior pelvic carbon-ion irradiation
Carbon-ion re-irradiation for pelvic recurrent rectal cancer
Japan |
pelvic recurrent rectal cancer
Radiology |
Malignancy
NO
The purpose of this study was to asses carbon ion radiation therapy performed as re-irradiation in patients with locally recurrent rectal cancer.
Safety,Efficacy
Confirmatory
Phase II
3 years survival rates
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
NO
NO
Institution is not considered as adjustment factor.
NO
1
Treatment
Device,equipment |
Heavy-ion particle irradaition
70.4Gy(RBE)/16fractions/4weeks
20 | years-old | <= |
Not applicable |
Male and Female
1. Confirmation of locally recurrent colorectal cancers in patients with prior carbon-ion irradiation
2. No invasion to digestive tracts, bladder or urethra
3.Not indicated for curative resection or does not wish to undergo surgery.
4.Has evaluable disease.
5.Without distant metastases by CT, MRI and PET findings
6. 20 years or older
7. Performance status between 0 and 2
8. Normal function of main organs
9.Presumed to be alive for at least 3 months.
10.Written consent to participate in this study has been obtained from the patient.
1. Diameter of treatment volume longer than 15cm
2.Patient receive chemotherapy within 2 weeks
3. If they have an open wound or a active inflammatory disease
4. If they have a concomitant malignancy
5. If they have a severe heart diseases, a severe cerebrovascular disorder, a severe diabetes, angina pectoris, cardiac infarction.
6.In appropriate for this clinical study because of mental disorder, or other severe concurrent disease.
7.Adults and minors who do not have the capacity to consent.
71
1st name | Shigeru |
Middle name | |
Last name | Yamada |
National Institute for Quantum and
Radiological Sciences and Technology
QST Hospital
206-8555
4-9-1 Anagawa, Inageku, Chiba 263-8555, Japan
043-206-3306
yamada.shigeru@qst.go.jp
1st name | Shigeru |
Middle name | |
Last name | Yamada |
National Institute for Quantum and Radiological Sciences and Technology
QST Hospital
263-8555
4-9-1 Anagawa, Inageku, Chiba 263-8555, Japan
043-206-3306
yamada.shigeru@qst.go.jp
National Institute for Quantum and
Radiological Sciences and Technology
QST hospital
National Institute for Quantum and
Radiological Sciences and Technology
Japanese Governmental office
National Institute for Quantum and Radiological Sciences and Technology
4-9-1 Anagawa, Inageku, Chiba, Japan
043-209-4706
helsinki@qst.go.jp
NO
2016 | Year | 06 | Month | 14 | Day |
Unpublished
No longer recruiting
2016 | Year | 05 | Month | 16 | Day |
2016 | Year | 05 | Month | 16 | Day |
2016 | Year | 06 | Month | 10 | Day |
2026 | Year | 03 | Month | 31 | Day |
2016 | Year | 06 | Month | 14 | Day |
2023 | Year | 06 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025839